Clinical trials: Brain Diseases, Metabolic
Diabetes Mellitus, Type 2, Diabetes Complications
Arterial Stiffness and Complication Risk in Type 2 Diabetes
Background The prevalence and incidence of type 2 diabetes is increasing globally. A common complication of diabetes is the disease of the blood vessels, vascular diseases, which can cause disorders like myocardial infarction…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Complications, Diabetic Angiopathies, Diabetic Nephropathies
- Trial name
- NCT02001532
- Where
- Denmark
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
TRIAL READY (Clinical Trial Readiness)
This study, being conducted under the auspice of the CReATe Consortium, will enroll patients with ALS and related disorders as well as healthy controls, with the goal of facilitating clinical validation of leading…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis
- Trial name
- NCT03912987
- Where
- 3 sites in United States
- Volunteers
- 610 people, healthy volunteers welcome
- Sponsor
- University of Miami
Pompe Disease
First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
This is an international, multi-center, open-label study designed to evaluate if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.
- Trial name
- NCT02675465
- Testing
- ATB200, AT2221
- Where
- 19 sites in United States, Australia and 4 more
- Volunteers
- 29 people
- Sponsor
- Amicus Therapeutics
Heart Diseases
Identifying Genes That May Increase the Risk for Heart Disease in African Americans
Heart disease and stroke disproportionately affect African Americans in the United States. These conditions are likely caused by both environmental and genetic factors.
- Trial name
- NCT00344136
- Where
- United States
- Volunteers
- 5,302 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Parkinson Disease, Parkinsonism
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
This is a two-center (University of Colorado, University of California San Francisco) community-based comparative effectiveness study of outpatient palliative care for Parkinson's disease (PD) and related disorders (progressive…
- Conditions
- Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive
- Trial name
- MTMD (NCT03076671)
- Testing
- Palliative Care
- Where
- 2 sites in United States
- Volunteers
- 783 people
- Sponsor
- University of Colorado, Denver
Cardiovascular Diseases, Overweight and Obesity
Impact of Milk Fat Globule Membrane Supplementation on Heart and Brain Health
In a randomised, controlled cross-over manner, this trial aims to determine how short-term daily supplementation with a milk fat globule membrane-enriched ingredient impacts on cardiometabolic health and cognitive outcomes.
- Conditions
- Cardiovascular Diseases, Overweight and Obesity, Cognition
- Trial name
- NCT05939544
- Testing
- Experimental: Milk Fat Globule Membrane-enriched Powdered Ingredient
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Loughborough University
Dementia
Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)
The purpose of this clinical trial is to test whether or not the medication amantadine is effective in reducing behavioral disturbances in patients with frontotemporal dementia.
- Trial name
- NCT00127114
- Testing
- Amantadine
- Where
- United States
- Sponsor
- Johns Hopkins University
Fabry's Disease, Chronic Pain
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain
Fabry disease is a rare inherited metabolic disorder that predominantly affects heart, kidneys and nervous system. Fabry disease has been searched in series of patients presenting different isolated signs caused by the affection…
- Trial name
- DOUFABIS (NCT02450604)
- Testing
- Diagnosis of Fabry disease
- Where
- 21 sites in France
- Volunteers
- 776 people
- Sponsor
- University Hospital, Bordeaux
Cardiovascular Diseases, Coronary Heart Disease
Umbrella Review and Updated Systematic Review and Meta-analysis of Pulses/Legumes and Incident Cardiometabolic Diseases
The European Association for the Study of Diabetes (EASD) guidelines have not made any specific recommendations regarding dietary pulses.
- Conditions
- Cardiovascular Diseases, Coronary Heart Disease, Stroke, Diabetes Mellitus, Type 2
- Trial name
- NCT03555734
- Testing
- Dietary pulses or legumes
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Diabetes, Alzheimer Disease
The Diabetes Prevention Program Outcomes Study AD/ADRD Project
The DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for…
- Conditions
- Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia
- Trial name
- DPPOS-4 (NCT05704309)
- Where
- 27 sites in United States
- Volunteers
- 1,976 people, healthy volunteers welcome
- Sponsor
- Marinella Temprosa
Diabetes
DHS MIND Metabolomics
The study team will evaluate whether metabolomic signatures of neurocognitive decline trajectories are exacerbated by the presence of type 2 diabetes mellitus (T2D) and whether these signatures contribute in part, to ethnic…
- Trial name
- NCT03975309
- Where
- United States
- Volunteers
- 417 people
- Sponsor
- Wake Forest University Health Sciences
Type 1 Diabetes Mellitus
Glycemic Control and the Brain in Children With Type 1 Diabetes
The purpose of this study is to determine if improving diabetes control by better controlling blood sugars, will help improve or normalize brain function as compared to routine diabetes care.
- Trial name
- NCT03428932
- Testing
- Closed Loop (Medtronic 670G), Standard Care
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Nemours Children's Clinic
Brain Death
Optical Assessment on Brain Death Via a Oxygen Supply Procedure
This study aims to evaluate brain death with optical probes. The changes of hemodynamic parameters including oxyhemoglobin (HbO2) and deoxyhemoglobin (Hb) were detected by near infrared spectroscopy probes attached on the…
- Trial name
- NCT03864887
- Testing
- Oxygen supply of high-low-high procedure, Oxygen supply of low-high-low procedure, Optical monitor for hemodynamic parameter.
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Retinitis Pigmentosa, Maculopathy, Age Related
High Resolution, High-speed Multimodal Ophthalmic Imaging
Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging.
- Conditions
- Retinitis Pigmentosa, Maculopathy, Age Related, Macular Dystrophy, Macular Edema
- Trial name
- IMA-MODE (NCT04129021)
- Testing
- High-resolution retinal imaging through adaptive optics, High-resolution retinal imaging through holographic systems
- Where
- France
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Intracranial Sacciform Aneurysm
Evaluation of Intestinal Microbiota Implication in Ruptured Intracranial Aneurysm
The physiopathology of intracranial aneurysm from initiation to ruptured is incompletely understood but included inflammation. The microbiota is known to interact with brain and can promote inflammation.
- Trial name
- AneBiote (NCT05914636)
- Testing
- analysis of foecal microbiota
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon
Friedreich Ataxia
Micronised Resveratrol as a Treatment for Friedreich Ataxia
The aim of this study is to assess the efficacy of micronised resveratrol as a treatment for FRDA, in terms of reducing the severity of ataxia symptoms at 24 weeks, through a randomised blinded, placebo controlled crossover trial.
- Trial name
- NCT03933163
- Testing
- Resveratrol
- Where
- 4 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Murdoch Childrens Research Institute
Primary Progressive Aphasia, Semantic Dementia
Primary Progressive Aphasia Multicomponent Language Treatment Study
The goal of this clinical trial is to learn if a speech-language telerehabilitation helps improve communication in people with primary progressive aphasia (PPA), a form of dementia that affects speech and language.
- Conditions
- Primary Progressive Aphasia, Semantic Dementia, Semantic Memory Disorder, Logopenic Progressive Aphasia
- Trial name
- NCT06649084
- Testing
- Multicomponent Lexical Retrieval Training (Multi-LRT), Multicomponent Video Implemented Script Training in Aphasia (Multi-VISTA), Multicomponent Communication Partner Training (Multi-CPT)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Texas at Austin
Hepatic Encephalopathy
Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy
This is a global study to compare the effects of AXA1665, an orally active mixture of amino acids, compared to placebo, on cognitive and physical function, as well as the safety and tolerability of AXA1665.
- Trial name
- EMMPOWER (NCT04816916)
- Testing
- AXA1665
- Where
- 40 sites in United States, Canada and 5 more
- Volunteers
- 12 people
- Sponsor
- Axcella Health, Inc
Gaucher Disease, Type 1, Gaucher Disease, Type 3
Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
Multicenter, doubleblinded, randomized placebo-controlled study of arimoclomol in patients with Gaucher Disease Type 1 or 3
- Trial name
- NCT03746587
- Testing
- Arimoclomol
- Where
- 8 sites in India
- Volunteers
- 39 people
- Sponsor
- ZevraDenmark
Fabry Disease
A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease
The main aim of the study is to assess the safety of REPLAGAL. Study participants will receive REPLAGAL as an intravenous infusion every other week for 52 weeks.
- Trial name
- NCT04974749
- Testing
- REPLAGAL
- Where
- 6 sites in China
- Volunteers
- 20 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.